Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.
Angola
Blood donors
COVID-19
Luanda
SARS-CoV-2
Seroprevalence
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
02 Nov 2021
02 Nov 2021
Historique:
received:
20
04
2021
accepted:
25
10
2021
entrez:
3
11
2021
pubmed:
4
11
2021
medline:
5
11
2021
Statut:
epublish
Résumé
SARS-CoV-2 emerged in China and spread throughout the world due to its rapid transmission. The exposure rate in the healthy population is unknown, mainly in resource-limited countries. Herein, we estimated the seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among blood donors in Luanda, the capital city of Angola. This was a retrospective study conducted with 343 blood donors. Chi-square and logistic regression were calculated to predict the independent variable for SARS-CoV-2 infection and deemed significant when p < 0.05. Seroprevalence of anti-SARS-CoV-2 was 4.7%. Positivity rates varied to age groups (3.5-14.3%), gender (0-5%), area of residence (3.1-.6%), educational level (5.1-10.2%), occupation (4.4-7.7%), and the blood donor category (2.0-5.1%). Past and recent infections were detected in 3.2% and 1.5%, respectively. Blood donors under the age of 20 years (OR: 4.58, p = 0.241) and from non-urbanized areas (OR: 1.86, p = 0.293) presented a high risk related to infection. The infection was higher in blood group A and lower in blood group O. The risk of SARS-CoV-2 infection has increased from January 2020 (OR: 0.03, p = 0.001) to August 2020 (OR: 0.57, p = 0.426). We provide an estimate of the exposure of healthy blood donors in Luanda. Also, we detected anti-SARS-CoV-2 in January 2020, indicating that the SARS-CoV-2 could have been imported during the first month of 2020. Further studies should be performed to assess the exposure rate in different groups from Angola.
Sections du résumé
BACKGROUND
BACKGROUND
SARS-CoV-2 emerged in China and spread throughout the world due to its rapid transmission. The exposure rate in the healthy population is unknown, mainly in resource-limited countries. Herein, we estimated the seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among blood donors in Luanda, the capital city of Angola.
METHODS
METHODS
This was a retrospective study conducted with 343 blood donors. Chi-square and logistic regression were calculated to predict the independent variable for SARS-CoV-2 infection and deemed significant when p < 0.05.
RESULTS
RESULTS
Seroprevalence of anti-SARS-CoV-2 was 4.7%. Positivity rates varied to age groups (3.5-14.3%), gender (0-5%), area of residence (3.1-.6%), educational level (5.1-10.2%), occupation (4.4-7.7%), and the blood donor category (2.0-5.1%). Past and recent infections were detected in 3.2% and 1.5%, respectively. Blood donors under the age of 20 years (OR: 4.58, p = 0.241) and from non-urbanized areas (OR: 1.86, p = 0.293) presented a high risk related to infection. The infection was higher in blood group A and lower in blood group O. The risk of SARS-CoV-2 infection has increased from January 2020 (OR: 0.03, p = 0.001) to August 2020 (OR: 0.57, p = 0.426).
CONCLUSIONS
CONCLUSIONS
We provide an estimate of the exposure of healthy blood donors in Luanda. Also, we detected anti-SARS-CoV-2 in January 2020, indicating that the SARS-CoV-2 could have been imported during the first month of 2020. Further studies should be performed to assess the exposure rate in different groups from Angola.
Identifiants
pubmed: 34727874
doi: 10.1186/s12879-021-06814-0
pii: 10.1186/s12879-021-06814-0
pmc: PMC8562364
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1131Informations de copyright
© 2021. The Author(s).
Références
Clin Infect Dis. 2021 Jul 15;73(2):328-331
pubmed: 32750119
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
JAMA Intern Med. 2020 Jul 21;:
pubmed: 32692365
Blood Transfus. 2021 May;19(3):181-189
pubmed: 33539289
Transfus Med Rev. 2020 Apr;34(2):75-80
pubmed: 32107119
Int J Infect Dis. 2021 Mar;104:452-457
pubmed: 33465488
Euro Surveill. 2020 Jul;25(28):
pubmed: 32700672
PLoS One. 2021 Feb 25;16(2):e0247852
pubmed: 33630977
Rev Saude Publica. 2020;54:69
pubmed: 32638883
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Br J Haematol. 2020 Jul;190(1):24-27
pubmed: 32379894
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Res Sq. 2021 Feb 12;:
pubmed: 33594353
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Transfus Apher Sci. 2020 Dec;59(6):102923
pubmed: 32868226
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Nat Med. 2020 Aug;26(8):1193-1195
pubmed: 32504052
Science. 2021 Jan 1;371(6524):79-82
pubmed: 33177105
Clin Infect Dis. 2021 Jan 27;72(2):249-253
pubmed: 33501969
JAMA. 2005 Mar 23;293(12):1450-1
pubmed: 15784866
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet Infect Dis. 2021 Apr;21(4):473-481
pubmed: 33338441
PLoS One. 2021 Mar 25;16(3):e0249249
pubmed: 33765102
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Transfusion. 2021 Mar;61(3):862-872
pubmed: 33527398